Recent Financings of Private Companies (12/2011)
This article was originally published in Start Up
Executive Summary
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research/analytical instrumentation and reagent sectors.
You may also be interested in...
Deals In Depth: October 2020
Two-year-old Insitro penned a potential $2.07bn collaboration with Bristol Myers Squibb focused on the discovery and development of therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The start-up will apply its ISH platform to create induced pluripotent stem cell-derived disease models. BMS also announced a definitive agreement to acquire MyoKardia for $13.1bn in cash. Financing reached $10.4bn in biopharma, $1.4bn in device, and $1.7bn in diagnostics.
Dealmaking: Q3 Roundup Shows Deal Values Jump From Prior Quarter
Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
Financing: Q3 Roundup Shows Fall In Device Company Activity But A Rise In IVDs
During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.
Need a specific report? 1000+ reports available
Buy Reports